Growth Hormone Secretagogues is a recurring topic in our peptide coverage. This hub collects every article tagged Growth Hormone Secretagogues, newest first, each evidence-graded and tied to real, verifiable sources.
The complete alphabetical directory of every peptide in the PeptideVox library — each with its class, highest-confidence evidence grade, and a plain-language summary that keeps human trial data strictly separate from animal, in-vitro and anecdote.
An evidence-graded review of the peptides marketed for athletic recovery — BPC-157, ipamorelin, CJC-1295 and TB-500. The honest 2026 verdict: every one is Grade C or D for recovery as an outcome, none is FDA-approved, and all are WADA-banned at all times.
A clinical monograph on CJC-1293 — an abandoned albumin-binding GHRH analog from the ConjuChem program that produced CJC-1295. No dedicated human data exist; the evidence grade is D, and it is explicitly banned by WADA.
A clinical monograph on examorelin — the International Nonproprietary Name for hexarelin, a synthetic hexapeptide growth-hormone secretagogue. Small human pharmacodynamic trials (Grade B), never approved, and WADA-prohibited at all times.
A clinical monograph on MK-677 (ibutamoren) — the oral, non-peptide ghrelin-receptor agonist that reliably raises GH and IGF-1, yet failed its clinical disease endpoints and carries a congestive-heart-failure safety signal.
A clinical monograph on ipamorelin — the selective growth-hormone secretagogue famous for the CJC-1295 stack. One human PD study, one failed RCT, and an unsettled 2026 legal status.
A clinical monograph on the tesamorelin + ipamorelin stack — a GHRH-analog plus ghrelin-receptor agonist combination marketed for body composition. Sound mechanism, Grade-A component data, but zero RCTs of the combination itself.
A clinical monograph on hexarelin (examorelin) — one of the most potent growth-hormone-releasing peptides. Real human GH-provocation and acute cardiac data (Grade B), preclinical cardioprotection claims (Grade C), and a 2026 status that is unapproved and banned in sport.
A clinical monograph on GHRP-6 — the first-generation ghrelin-receptor agonist that reliably triggers a growth hormone pulse and a potent appetite surge. Real but small human data, no therapeutic RCTs, and a restricted 2026 legal status.
A clinical monograph on GHRP-2 (pralmorelin) — the ghrelin-receptor agonist approved in Japan as a single-dose GH-deficiency diagnostic. Grade-A acute GH provocation, no chronic-use evidence, and a restrictive 2026 legal status.
A clinical monograph on CJC-1295 without DAC (Mod GRF 1-29) — the short-acting, pulse-preserving GHRH analog. Solid preclinical pharmacology, no human RCT of the no-DAC molecule, and an unsettled 2026 legal status.
A clinical monograph on CJC-1295 with DAC — the albumin-tethered, long-acting GHRH analog. Small Phase 1 RCTs prove it raises GH and IGF-1 for days (Grade B), but no clinical-outcome trial exists, and it is unapproved and banned in sport.
Growth Hormone Secretagogues is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged Growth Hormone Secretagogues, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.